uploads/2018/02/Bosulif.png

Pfizer’s Bosulif Had a Strong Performance in 4Q17 and 2017

By

Updated

Bosulif revenue trends

In 4Q17, Pfizer’s (PFE) Bosulif generated revenues of $70 million, which reflected ~52% growth on a YoY (year-over-year) basis.

In 4Q17, in the US and international markets, Bosulif reported revenues of $46 million and $24 million, respectively—compared to $31 million and $15 million in 4Q16, which reflects ~50% and 55% growth on a YoY basis.

In fiscal 2017, Bosulif reported revenues of $233 million, which is ~39% growth on a YoY basis. In 2017, in the US and international markets, Bosulif generated revenues of $156 million and $77 million, respectively—compared to $115 million and $52 million in 2016.

In developed European markets and emerging markets in 2017, Bosulif reported revenues of $40 million and $5 million, respectively—compared to $28 million and $2 million in 4Q16.

Article continues below advertisement

Recent developments

In December 2017, the FDA approved Pfizer’s sBLA (supplemental new drug application) to expand the use of Bosulif to treat adults with newly-diagnosed chronic phase Philadelphia chromosome-positive CML (chronic myelogenous leukemia).

The FDA approval for Bosulif’s label expansion was based on data from the phase 3 BFORE trial. In the phase 3 BFORE trial, a significantly higher rate of patients on Bosulif achieved major molecular response (or MMR) at 12 months—compared to patients on imatinib.

At 12 months, patients on Bosulif had a CCyR (complete cytogenic response) rate of 77.2%—compared to 66.4% for patients on imatinib.

In September 2012, Bosilif received FDA approval to treat adults with chronic accelerated Philadelphia chromosome-positive CML.

Bosulif’s label expansion in December 2017 is expected to boost the drug’s sales in 2018.

In the CML drugs market, Bosulif’s peers include Takeda Pharmaceuticals’ (TKPYY) Iclusig, Bristol-Myers Squibb’s (BMY) Sprycel, and Novartis’s (NVS) Tasigna.

Advertisement

More From Market Realist